Company intelligence / Profile preview

Инженерные Системы

Ownership: Private
Development stage: Other

Overview

Sistema Biotech develops and commercializes diagnostic test systems, including genetic/DNA tests for medical and veterinary use. The company also offers contract development services for recombinant proteins, monoclonal antibodies, bispecific antibodies, and biosimilars using its proprietary CHO-SBT cell line platform. Its diagnostic products include COVID‑19 RNA detection kits. There is no evidence of clinical-stage therapeutics as of now.

Modalities: Recombinant proteinMonoclonal antibodyBispecific monoclonal antibodyDiagnostic test system
Industry: Molecular Diagnostics

Partnerships

МОСМЕДПАРК innovation cluster

Beyond the preview

Go deeper on Инженерные Системы.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Инженерные Системы.

Explore the full profile